Wickens, Mark
AstraZeneca (United Kingdom)
2 papers on CoChat
Most cited papers
- Verified
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet
PARP inhibition in cancer therapyBRCA gene mutations in cancer
Cited by 2,279
- Verified
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet
PARP inhibition in cancer therapyBRCA gene mutations in cancer
Cited by 1,655
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free